PEDS1-UBE2V1 as A Potential Drug Target for Alzheimer's (G387522)

Target Name: PEDS1-UBE2V1

NCBI ID: G387522

PEDS1-UBE2V1

PEDS1-UBE2V1 as A Potential Drug Target for Alzheimer's

PEDS1-UBE2V1 (TMEM189-UBE2V1) as a Drug Target and Biomarker: A Promising Potential Target for the Treatment of Alzheimer's Disease

Abstract:

Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide, leading to a significant impact on the quality of life of patients and their caregivers. The identification of potential drug targets and biomarkers for the disease has the potential to significantly advance the development of new treatments. In this article, we focus on PEDS1-UBE2V1 (TMEM189-UBE2V1), a promising potential drug target and biomarker for Alzheimer's disease.

Introduction:

Alzheimer's disease is a neurodegenerative disorder that is characterized by a progressive accumulation of neurofibrillary tangles and senile plaques in the brain. The most common cause of Alzheimer's disease is the presenile dementia, which is a natural part of the aging process. As the number of people with Alzheimer's disease increases, the demand for effective treatments increases. Therefore, the development of new treatments for Alzheimer's disease has the potential to significantly improve the quality of life of patients.

PEDS1-UBE2V1 (TMEM189-UBE2V1) as a Potential Drug Target:

PEDS1-UBE2V1 (TMEM189-UBE2V1) is a protein that is expressed in the brain and has been shown to play a role in the development and progression of Alzheimer's disease. The PEDS1 gene is located on chromosome 12 and encodes a protein that is involved in the regulation of synaptic plasticity and in the modulation of neurotransmitter release. The UBE2V1 gene is located on chromosome 22 and encodes a protein that is involved in the regulation of

Protein Name: PEDS1-UBE2V1 Readthrough

Functions: Has no ubiquitin ligase activity on its own. The UBE2V1-UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through Lys-63. This type of poly-ubiquitination activates IKK and does not seem to involve protein degradation by the proteasome. Plays a role in the activation of NF-kappa-B mediated by IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. Together with RNF135 and UBE2N, catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of RIGI to activate the downstream signaling pathway that leads to interferon beta production (PubMed:31006531). UBE2V1-UBE2N together with TRAF3IP2 E3 ubiquitin ligase mediate 'Lys-63'-linked polyubiquitination of TRAF6, a component of IL17A-mediated signaling pathway

The "PEDS1-UBE2V1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEDS1-UBE2V1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets